This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Vu, T. H. Articles by Hoffman, A. R. Search for Related Content PubMed PubMed Citation Articles by Vu, T. H. Articles by Hoffman, A. R.

Loss of Imprinting of IGF2 Sense and Antisense Transcripts in Wilms’ Tumor¹

Medical Service, VA Palo Alto Health Care System and the Department of Medicine, Stanford University School of Medicine, Palo Alto,California 94304 [T. H. V., T. L., A. R. H.], and the Department of Food and Nutrition, Japan Women’s University, Tokyo 113, Japan [N. V. C.]

Human insulin-like growth factor II gene (IGF2) is overexpressed, and its imprinting is disrupted in many tumors, including Wilms’ tumor. A transcript that is antisense to IGF2, IGF2-antisense (IGF2-AS), is transcribed from within IGF2 in a reverse orientation. This transcript is also maternally imprinted and overexpressed in Wilms’ tumor. IGF2-AS was detected as a 2.2 kb mRNA in Hep 3B cells by Northern blotting, and it encodes a putative 168 amino acid peptide. An alternative splicing mRNA observed predominantly in adult liver encodes an additional putative 199 amino acid peptide. We have examined the expression of IGF2 and IGF2-AS in normal tissue, breast and ovarian tumors, and 25 informative, well-characterized Wilms’ tumors and determined the relationship between IGF2 and IGF2-AS imprinting. IGF2-AS was expressed at levels comparable with IGF2 sense expression derived from promoters P1 and P2 in normal tissue and in breast, ovarian, and Wilms’ tumor tissues. In Wilms’ tumors that demonstrate maintenance of imprinting of IGF2, IGF2-AS was imprinted. In contrast, in tumors which demonstrate LOI of IGF2, only two of six tumors showed loss of imprinting of IGF2-AS, whereas four of six tumors demonstrated maintenance of imprinting for IGF2-AS. The discrepancy between IGF2 and IGF2-AS loss of imprinting in some tumors demonstrates the control complexity of the imprinting status of the various transcripts derived from the IGF2 gene.

This article has been cited by other articles:

				A. R. Dallosso, A. L. Hancock, S. Malik, A. Salpekar, L. King-Underwood, K. Pritchard-Jones, J. Peters, K. Moorwood, A. Ward, K. T.A. Malik, et al. Alternately spliced WT1 antisense transcripts interact with WT1 sense RNA and show epigenetic and splicing defects in cancer RNA, December 1, 2007; 13(12): 2287 - 2299. [Abstract] [Full Text] [PDF]

				J. M. Devaney, E. P. Hoffman, H. Gordish-Dressman, A. Kearns, E. Zambraski, and P. M. Clarkson IGF-II gene region polymorphisms related to exertional muscle damage J Appl Physiol, May 1, 2007; 102(5): 1815 - 1823. [Abstract] [Full Text] [PDF]

				L. Soroceanu, S. Kharbanda, R. Chen, R. H. Soriano, K. Aldape, A. Misra, J. Zha, W. F. Forrest, J. M. Nigro, Z. Modrusan, et al. Identification of IGF2 signaling through phosphoinositide-3-kinase regulatory subunit 3 as a growth-promoting axis in glioblastoma PNAS, February 27, 2007; 104(9): 3466 - 3471. [Abstract] [Full Text] [PDF]

				D. Prawitt, T. Enklaar, B. Gartner-Rupprecht, C. Spangenberg, M. Oswald, E. Lausch, P. Schmidtke, D. Reutzel, S. Fees, R. Lucito, et al. Microdeletion of target sites for insulator protein CTCF in a chromosome 11p15 imprinting center in Beckwith-Wiedemann syndrome and Wilms' tumor PNAS, March 15, 2005; 102(11): 4085 - 4090. [Abstract] [Full Text] [PDF]